Unexpected discovery of multiple myeloma following cardiomyopathy

Dahraoui, Souhail; Uwingabiye, Jean; Belarj, Badia; Biaz, Asmae; Rachid, Achraf; Dami, Abdellah; Bouhsain, Sanae; Ouzzif, Z.; Idrissi, S.

doi:10.1002/ccr3.1297

Cited by 2 publications

(4 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Myocardial involvement is estimated to be present in half of the amyloid light chain amyloidosis cases, which may subsequently result into restrictive physiology and CM [30,34]. These findings support the observation made in several case reports of the relationship between MM and amyloidosis in the development of CM [29,30]. MM has also been associated with a specific set of clinical manifestations often referred to as CRAB (elevated Calcium levels, Renal insufficiency, Anaemia and Bone lesions), which may increase the risk of CV comorbidities [35].…”

Section: Haematologic Cardiomyopathysupporting

confidence: 70%

“…It is the second most prevalent haematological malignant abnormality with an annual age-adjusted incidence of 6.3 per 100,000 persons in the U.S. [24] and accounts for approximately 10% of all haematological cancers [26][27][28]. Anaemia is a common complication observed in about two-thirds of MM patients [29]. A triad of chronic kidney disease, HF and anaemia has been described in clinical practice [29,30].…”

Section: Haematologic Cardiomyopathymentioning

confidence: 99%

“…Anaemia is a common complication observed in about two-thirds of MM patients [29]. A triad of chronic kidney disease, HF and anaemia has been described in clinical practice [29,30]. The risk of CV and thrombotic events is an import consideration during treatment of MM patients because CV risk factors and CVD are prevalent in the MM patient population, and CV and thrombotic complications are associated with MM itself.…”

Section: Haematologic Cardiomyopathymentioning

confidence: 99%

See 2 more Smart Citations

Hematologic/Oncologic cardiomyopathy: A review and pooled analysis of pathophysiology, diagnosis and clinical management

Albakri¹

2019

Clin Med Invest

View full text Add to dashboard Cite

Marked improvement in the accuracy and sensitivity of current diagnostic techniques for cardiac diseases have contributed to the identification of haematologic and oncologic diseases as a possible aetiology of cardiomyopathy (CM). If undiagnosed, the CM may progress to HF and eventually death. This type of CM is exceedingly rare and a precise understanding of its natural cause, pathophysiology, diagnosis and management is undermined by the lack of supporting clinical evidence. Cancer as a direct cause of CM remains controversial. Differentiating cancer-associated CM from chemotherapy-induced CM is difficult since diagnosis of CM is nearly always made after the initiation chemotherapy. Hematologic diseases on the other hand have been classified under restrictive cardiomyopathy (RCM) or dilated cardiomyopathy (DCM) yet they are a distinct clinical entity uniquely characterized by cardiac chamber (atrial and/or ventricular) dilation, diastolic dysfunction and preserved systolic function. Oncologic or haematologic CM has an ominous prognosis although diagnosis is incidental or delayed making management difficult. There is a need to better understand the role of oncologic and/or haematologic diseases in the pathogenesis of CM aimed to improve diagnosis and development of aetiology-specific therapy. Similarly, this review provides an overview of CM in oncology and haematology patients including pathophysiology, presentation, diagnosis and treatment.

show abstract

Section: Haematologic Cardiomyopathysupporting

confidence: 70%

Section: Haematologic Cardiomyopathymentioning

confidence: 99%

Section: Haematologic Cardiomyopathymentioning

confidence: 99%

See 1 more Smart Citation

Hematologic/Oncologic cardiomyopathy: A review and pooled analysis of pathophysiology, diagnosis and clinical management

Albakri¹

2019

Clin Med Invest

View full text Add to dashboard Cite

show abstract

“…Various studies have analyzed the pathogenesis of ACM, which includes cardiac toxicity induced by the principal metabolites of ethanol ( 17 , 18 ), apoptosis ( 19 ), mitochondrial dysfunction ( 20 ) and abnormal energy metabolism of cardiomyocytes, nutrient imbalance, ventricular remodeling ( 21 , 22 ), disorders of the neurohumoral system ( 23 , 24 ), abnormal cell signal transduction and immunological and inflammatory reactions ( 25 ). Studies have reported that ethanol-induced apoptosis serves a key role in the pathogenesis of ACM ( 26 – 29 ). A study on the mechanism of ethanol-induced cardiomyocyte apoptosis demonstrated that the levels of tumor necrosis factor-α, the apoptotic protein Bcl-2-associated X and caspase-3 are significantly increased in ACM ( 30 ).…”

Section: Discussionmentioning

confidence: 99%

MicroRNA‑186‑5p is expressed highly in ethanol‑induced cardiomyocytes and regulates apoptosis via the target gene XIAP

Liu

2019

Mol Med Report

View full text Add to dashboard Cite

Ethanol has a toxic effect on the heart, resulting in cardiomyocyte damage. Long-term high intake of ethanol leads to a non-ischemic dilated cardiomyopathy termed alcoholic cardiomyopathy (ACM). However, the pathogenesis of alcoholic cardiomyopathy remains unclear. The apoptosis of cardiomyocytes serves an important role in the pathogenesis of ACM. X-linked inhibitor of apoptosis protein (XIAP) is an important anti-apoptotic protein in human tissue cells. To the best of our knowledge, no studies have reported on its function in ethanol-induced cardiomyopathy. Previous works have screened the ACM-associated differentially expressed microRNAs (miRs), including miR-186-5p and miR-488-3p. TargetScan bioinformatics software was used to predict 949 target genes associated with miR-186-5p, and XIAP was demonstrated to be a target of miR-186-5p. The present study firstly analyzed the levels of apoptosis in ethanol-treated cardiomyocytes using flow cytometry. Alterations in the expression levels of miR-186-5p and XIAP were subsequently evaluated in ethanol-treated AC16 cardiomyocytes to assess the specific molecular mechanisms of ethanol-induced cardiomyocyte apoptosis. The levels of apoptosis in AC16 cardiomyocytes increased following ethanol treatment, and further increased with the rise in concentration and action time of ethanol. The expression levels of miR-186-5p were upregulated, and the expression levels of XIAP were downregulated in ethanol-treated cardiomyocytes. miR-186-5p may regulate ethanol-induced apoptosis in cardiomyocytes using XIAP as the direct target gene. This study provides a novel therapeutic target for the prevention and treatment of ACM.

show abstract

Unexpected discovery of multiple myeloma following cardiomyopathy

Cited by 2 publications

References 10 publications

Hematologic/Oncologic cardiomyopathy: A review and pooled analysis of pathophysiology, diagnosis and clinical management

Hematologic/Oncologic cardiomyopathy: A review and pooled analysis of pathophysiology, diagnosis and clinical management

MicroRNA‑186‑5p is expressed highly in ethanol‑induced cardiomyocytes and regulates apoptosis via the target gene XIAP

Contact Info

Product

Resources

About